Prostate cancer - historical

Back to Top
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main prostate cancer page for current regimens.
Last updated on 2024-07-23:14 regimens on this page
16 variants on this page
 
=Hormonal therapy for locally advanced or metastatic disease=
==Castration==
===Regimen===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Parmar et al. 1985 	1984-01 to 1985-07 	Phase 3 (C)	D-Trp-6-LHRH 	Did not meet efficacy endpoints
Soloway et al. 1991 	Not reported 	Phase 3 (C)	Goserelin 	Did not meet efficacy endpoints
Robinson 1993 (EORTC 30805) 	1981-1986 	Phase 3 (C)	1. Castration & Cyproterone acetate2. DES	Did not meet endpoints of TTP/OS
Kaisary et al. 1991 	1983-1986 	Phase 3 (C)	Goserelin 	Did not meet efficacy endpoints
Keuppens et al. 1990 (EORTC 30853) 	1986-1988 	Phase 3 (C)	Flutamide & Goserelin 	Seems to have shorter OS1
Janknegt et al. 1993 (International Anandron Study)	1986 to not reported 	Phase 3 (C)	Nilutamide & Orchiectomy 	Shorter PFS
Bruun et al. 1996 	Not reported 	Phase 3 (C)	1. Buserelin2. Estrogens 	Did not meet endpoints of testosterone suppression/OS
Studer et al. 2004 (SAKK 08/88) 	1988-1992 	Phase 3 (C)	Orchiectomy; deferred 	Did not meet endpoint of OS
Boccon-Gibod et al. 1997 	1989-1991 	Phase 3 (C)	Flutamide 	Did not meet primary endpoint of PFS
de Voogt et al. 1998 (EORTC 30843) 	Not reported in abstract	Phase 3 (C)	Buserelin & Cyproterone acetate 	Did not meet endpoints of RR/TTP/OS
Eisenberger et al. 1998 	1989-1994 	Phase 3 (C)	Flutamide & Orchiectomy 	Did not meet primary endpoint of OS
Tyrrell et al. 1998 	Not reported in abstract	Phase 3 (C)	Bicalutamide 	Did not meet endpoint of OS2
de Reijke et al. 1999 	1990-1995 	Phase 3 (C)	Mitomycin & Orchiectomy 	Did not meet endpoints of TTP/PFS
Millikan et al. 2008 (MDA DM95-231) 	1996-2003 	Phase 3 (C)	ADT & KA/VE 	Did not meet primary endpoint of time to castrate-resistant progression
1Reported efficacy for EORTC 30853 is based on the 1998 final update.
2Reported efficacy for Tyrrell et al. 1998 is based on the 2000 update.
Note: This procedure is no longer widely used as monotherapy in the United States; included for reference purposes only. The full manuscripts for EORTC 30843 and Tyrrell et al. 1998 were not available for review.
====Endocrine therapy====
*Bilateral orchiectomy
===References===
# Parmar H, Phillips RH, Lightman SL, Edwards L, Allen L, Schally AV. Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet. 1985 Nov 30;2(8466):1201-5. link to original article EuroPMC
#EORTC 30853: Keuppens F, Denis L, Smith P, Carvalho AP, Newling D, Bond A, Sylvester R, De Pauw M, Vermeylen K, Ongena P; EORTC GU Group. Zoladex and flutamide versus bilateral orchiectomy: a randomized phase III EORTC 30853 study. Cancer. 1990 Sep 1;66(5 Suppl):1045-57. link to original article EuroPMC
##Update: Denis LJ, Carnelro de Moura JL, Bono A, Sylvester R, Whelan P, Newling D, De Pauw M; EORTC GU Group. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology. 1993 Aug;42(2):119-29. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
##Update: Denis LJ, Keuppens F, Smith PH, Whelan P, de Moura JL, Newling D, Bono A, Sylvester R; EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. Eur Urol. 1998;33(2):144-51. link to original article EuroPMC
# Soloway MS, Chodak G, Vogelzang NJ, Block NL, Schellhammer PF, Smith JA Jr, Scott M, Kennealey G, Gau TC; Zoladex Prostate Study Group. Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Urology. 1991 Jan;37(1):46-51. link to original article EuroPMC
## Update: Vogelzang NJ, Chodak GW, Soloway MS, Block NL, Schellhammer PF, Smith JA Jr, Caplan RJ, Kennealey GT; Zoladex Prostate Study Group. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Urology. 1995 Aug;46(2):220-6. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol. 1991 May;67(5):502-8. link to original article EuroPMC
# International Anandron Study: Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hahn L, Bracken B, Brisset JM, Da Silva FC, Chisholm G, Crawford ED, Debruyne FM, Dijkman GD, Frick J, Goedhals J, Knönagel H, Venner PM. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol. 1993 Jan;149(1):77-82. link to original article EuroPMC 
## Update: Janknegt RA; Anandron International Study Group. Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Cancer. 1993 Dec 15;72(12 Suppl):3874-7. link to original article EuroPMC
## Update: Dijkman GA, Janknegt RA, De Reijke TM, Debruyne FM; International Anandron Study Group. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. J Urol. 1997 Jul;158(1):160-3. link to original article EuroPMC
## Update: de Reijke T, Derobert E; Anandron /Nilutamide Study Group. Prognostic factor analysis in patients with advanced prostate cancer treated by castration plus anandron or placebo: a final update. Eur Urol. 2002 Aug;42(2):139-46. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# EORTC 30805: Robinson MR. A further analysis of European Organization for Research and Treatment of Cancer protocol 30805: orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose diethylstilbestrol. Cancer. 1993 Dec 15;72(12 Suppl):3855-7. link to original article EuroPMC
## Update: Robinson MR, Smith PH, Richards B, Newling DW, de Pauw M, Sylvester R. The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol. 1995;28(4):273-83. link to original article EuroPMC
# Bruun E, Frimodt-Møller C; Danish Buserelin Study Group. The effect of Buserelin versus conventional antiandrogenic treatment in patients with T2-4NXM1 prostatic cancer; A prospective, randomized multicentre phase III trial. Scand J Urol Nephrol. 1996 Aug;30(4):291-7. link to original article EuroPMC
# Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, Hubert J, Soret JY, Mangin P, Mallo C, Fraysse CE. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol. 1997;32(4):391-5. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
# EORTC 30843: de Voogt HJ, Studer U, Schröder FH, Klijn JG, de Pauw M, Sylvester R; EORTC Genito-Urinary Tract Cancer Cooperative Group. Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer: final analysis of EORTC GU Group Trial 30843. Eur Urol. 1998;33(2):152-8. link to original article EuroPMC
# Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM Jr, Bueschen AJ, Lowe BA. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998 Oct 8;339(15):1036-42. link to original article EuroPMC
# Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, Chamberlain M, Webster A, Blackledge G. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 1998;33(5):447-56. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
## Update: Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, Chamberlain M, Carroll K, Melezinek I. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol. 2000 Nov;164(5):1579-82. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# de Reijke TM, Keuppens FI, Whelan P, Kliment J, Robinson MR, Rea LA, Sylvester RJ; European Organisation for Research in Cancer Therapy Genitourinary Group. Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organisation for Research in Cancer Therapy Genitourinary Group trial. J Urol. 1999 Nov;162(5):1658-64. link to original article EuroPMC
# SAKK 08/88: Studer UE, Hauri D, Hanselmann S, Chollet D, Leisinger HJ, Gasser T, Senn E, Trinkler FB, Tscholl RM, Thalmann GN, Dietrich D. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol. 2004 Oct 15;22(20):4109-18. Erratum in: J Clin Oncol. 2005 Feb 1;23(4):936. link to original article EuroPMC
# MDA DM95-231: Millikan RE, Wen S, Pagliaro LC, Brown MA, Moomey B, Do KA, Logothetis CJ. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol. 2008 Dec 20;26(36):5936-42. Epub 2008 Nov 24. link to original article link to PMC article EuroPMC NCT00002855
# ECOG E8892: NCT00002881
==Cortisone monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence
Miller & Hinman 1954	Not reported 	Non-randomized
====Endocrine therapy====
*Cortisone
===References===
# Miller GM, Hinman F Jr. Cortisone treatment in advanced carcinoma of the prostate. J Urol. 1954 Sep;72(3):485-96. link to original article EuroPMC
==Cyproterone acetate monotherapy==
===Regimen variant #1, IM===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Jacobi et al. 1980	Not reported 	Phase 3 (E-switch-ic)	Estradiol undecylate	Seems to have higher ORR
====Endocrine therapy====
*Cyproterone acetate (Androcur) 300 mg IM once on day 1
7-day cycles
===Regimen variant #2, PO 200 mg/day===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Debruyne et al. 1998	1992-1994 	Phase 3 (C)	Liarozole 	Seems to have shorter OS
====Endocrine therapy====
*Cyproterone acetate (Androcur) 100 mg PO twice per day
Continued indefinitely
===Regimen variant #3, PO 250 mg/day===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Pavone-Macaluso et al. 1986 (EORTC 30761)	1977-1981 	Phase 3 (E-switch-ic)	1. DES 	Did not meet endpoint of OS
Pavone-Macaluso et al. 1986 (EORTC 30761)	1977-1981 	Phase 3 (E-switch-ic)	2. MPA 	Seems to have longer OS
====Endocrine therapy====
*Cyproterone acetate (Androcur) 250 mg PO once per day
Continued indefinitely
===References===
# Jacobi GH, Altwein JE, Kurth KH, Basting R, Hohenfellner R. Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial. Br J Urol. 1980 Jun;52(3):208-15. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
# EORTC 30761: Pavone-Macaluso M, de Voogt HJ, Viggiano G, Barasolo E, Lardennois B, de Pauw M, Sylvester R. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organisation for Research on Treatment of Cancer Urological Group. J Urol. 1986 Sep;136(3):624-31. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# Debruyne FJ, Murray R, Fradet Y, Johansson JE, Tyrrell C, Boccardo F, Denis L, Marberger JM, Brune D, Rassweiler J, Vangeneugden T, Bruynseels J, Janssens M, De Porre P; Liarozole Study Group. Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Urology. 1998 Jul;52(1):72-81. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==DES monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Smith et al. 1986 (EORTC 30762) 	1976-1980 	Phase 3 (E-switch-ic)	Estramustine 	Did not meet endpoint of OS
Osborne et al. 1990 (SWOG S8219)	1982-1986 	Phase 3 (C) 	AC & Orchiectomy	Did not meet endpoints of TTF/OS
Waymont et al. 1992 	1985-1987 	Phase 3 (C) 	Goserelin 	Seems to have lower TTFR
Note: No longer used, but of historical interest.
====Endocrine therapy====
*Diethylstilbestrol (DES) 3 mg PO once per day
Continued indefintely
===References===
# EORTC 30762: Smith PH, Suciu S, Robinson MR, Richards B, Bastable JR, Glashan RW, Bouffioux C, Lardennois B, Williams RE, de Pauw M, Sylvester R. A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organisation for Research on Treatment of Cancer. J Urol. 1986 Sep;136(3):619-23. link to original article EuroPMC
# SWOG S8219: Osborne CK, Blumenstein B, Crawford ED, Coltman CA Jr, Smith AY, Lambuth BW, Chapman RA. Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study. J Clin Oncol. 1990 Oct;8(10):1675-82. link to original article EuroPMC
# Waymont B, Lynch TH, Dunn JA, Emtage LA, Arkell DG, Wallace DM, Blackledge GR. Phase III randomised study of zoladex versus stilboestrol in the treatment of advanced prostate cancer. Br J Urol. 1992 Jun;69(6):614-20. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
=Chemotherapy for metastatic disease=
==CMF==
CMF: Cyclophosphamide, Methotrexate, 5-Fluorouracil
===Regimen===
Study 	Dates of enrollment	Evidence
Wozniak et al. 1993	1985-01 to 1985-06 	Phase 2
Note: This regimen is "minimally active in hormone-refractory metastatic prostate cancer" per Wozniak et al. 1993 and is included for historical reference only.
====Chemotherapy====
*Cyclophosphamide (Cytoxan) 100 mg/m2 PO once per day on days 1 to 7
*Methotrexate (MTX) 15 mg/m2 IV once on day 1
*Fluorouracil (5-FU) 300 mg/m2 IV once on day 1
7-day cycles
===References===
# Wozniak AJ, Blumenstein BA, Crawford ED, Boileau M, Rivkin SE, Fletcher WS; SWOG. Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer: a Southwest Oncology Group study. Cancer. 1993 Jun 15;71(12):3975-8. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==Suramin monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Small et al. 2002 (CALGB 9480)	1995-12 to 1996-12 	Phase 3 (C)	1. Suramin; intermediate-dose2. Suramin; high-dose	Did not meet primary endpoint of RR
====Chemotherapy====
*Suramin (Antrypol) as follows:
**Cycle 1: 600 mg/m2 IV once on day 1, then 300 mg/m2 IV once per day on days 2 & 8, then 240 mg/m2 IV once on day 9
**Cycle 2: 300 mg/m2 IV once on day 1, then 240 mg/m2 IV once per day on days 2 & 8, then 192 mg/m2 IV once on day 9
**Cycle 3: 240 mg/m2 IV once on day 1, then 192 mg/m2 IV once per day on days 2 & 8, then 156 mg/m2 IV once on day 9
28-day cycle for 3 cycles
===References===
#CALGB 9480: Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. J Clin Oncol. 2002 Aug 15;20(16):3369-75. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00002723
==Suramin & Hydrocortisone==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Small et al. 2000	1994-1996 	Phase 3 (E-esc)	Hydrocortisone	Longer TTP (secondary endpoint)
====Endocrine therapy====
*Hydrocortisone (Cortef) 40 mg/day PO
====Chemotherapy====
*Suramin (Antrypol) 1000 mg/m2 IV over 2 hours once on day 1, then 400 mg/m2 IV over 60 minutes once on day 2, then 300 mg/m2 IV over 60 minutes once on day 3, then 250 mg/m2 IV over 60 minutes once on day 4, then 200 mg/m2 IV over 60 minutes once on day 5, then 275 mg/m2 IV over 60 minutes once per day on days 8, 11, 15, 19, 22, 29, 36, 43, 50, 57, 64, 71, 78
78-day course
===References===
#Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, Lenehan PF, Chen L, Slichenmyer WJ, Eisenberger M. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol. 2000 Apr;18(7):1440-50. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
=Therapy for metastatic castrate-resistant disease=
==Aspirin & Dexamethasone==
DA: Dexamethasone & Aspirin
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Shamash et al. 2011 (BARTS-DAVDAS)	2001-2008 	Phase 3 (C)	Aspirin, Dexamethasone, Diethylstilbestrol	Did not meet primary endpoint of ORR
====Endocrine therapy====
*Dexamethasone (Decadron) 2 mg PO once per day
====Supportive therapy====
*Aspirin 75 mg PO once per day
*Ranitidine (Zantac) 150 mg PO twice per day
Continued indefinitely
===References===
# BARTS-DAVDAS: Shamash J, Powles T, Sarker SJ, Protheroe A, Mithal N, Mills R, Beard R, Wilson P, Tranter N, O'Brien N, McFaul S, Oliver T. A multi-centre randomised phase III trial of dexamethasone vs dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred diethylstilbestrol. Br J Cancer. 2011 Feb 15;104(4):620-8. Epub 2011 Feb 1. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00316927
==Cyclophosphamide monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Saxman et al. 1992	1984-1989 	Phase 3 (C)	CAM 	Did not meet endpoint of OS
====Chemotherapy====
*Cyclophosphamide (Cytoxan) 1000 mg/m2 IV once on day 1
21-day cycles
===References===
# Saxman S, Ansari R, Drasga R, Miller M, Wheeler B, McClean J, Einhorn L; Hoosier Oncology Group. Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer: a Hoosier Oncology Group study. Cancer. 1992 Nov 15;70(10):2488-92. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==Cyclophosphamide, Prednisone, Diethylstilbestrol==
CPD: Cyclophosphamide, Prednisone, Diethylstilbestrol
===Regimen===
Study 	Dates of enrollment	Evidence	Efficacy
Hellerstedt et al. 2003	1998-09 to 2001-07 	Phase 2 	50% or greater decline in PSA: 42%
====Chemotherapy====
*Cyclophosphamide (Cytoxan) 100 mg PO once per day on days 1 to 20
====Endocrine therapy====
*Prednisone (Sterapred) 10 mg PO once per day on days 1 to 30
*Diethylstilbestrol (DES) 1 mg PO once per day on days 1 to 30
====Supportive therapy====
*Warfarin (Coumadin) 1 mg PO once per day to decrease risk of DVT
30-day cycles
===References===
#Hellerstedt B, Pienta KJ, Redman BG, Esper P, Dunn R, Fardig J, Olson K, Smith DC. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. Cancer. 2003 Oct 15;98(8):1603-10. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==Doxorubicin monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Leaf et al. 2003 (ECOG E3882)	1983-1986 	Phase 3 (C) 	Doxorubicin & DES 	Did not meet endpoint of OS
Tu et al. 2001 	1996-1999 	Randomized Phase 2 (C)	Doxorubicin & Strontium-89	Shorter OS
====Chemotherapy====
*Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
21-day cycles
===References===
# Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001 Feb 3;357(9253):336-41. Erratum in: Lancet 2001 Apr 14;357(9263):1210. link to original article EuroPMC
# ECOG E3882: Leaf AN, Propert K, Corcoran C, Catalano PJ, Trump DL, Harris JE, Davis TE. Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): an Eastern Cooperative Oncology Group study. Med Oncol. 2003;20(2):137-46. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==Doxorubicin & Strontium-89==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Tu et al. 2001	1996-1999 	Randomized Phase 2 (E-esc)	Doxorubicin	Longer OS
====Preceding treatment====
*Doxorubicin & Ketoconazole alternating with Estramustine & Vinblastine
====Chemotherapy====
*Doxorubicin (Adriamycin) (dose not specified) IV once per day on days 1, 8, 15, 22, 29, 36
====Radiotherapy====
*Strontium-89 (Metastron) 2.035 MBq/kg IV once during week 1, given after the first dose of doxorubicin
6-week course
====Subsequent treatment====
*Ketoconazole maintenance
===References===
# Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001 Feb 3;357(9253):336-41. Erratum in: Lancet 2001 Apr 14;357(9263):1210. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==Vinblastine monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Hudes et al. 1999	1993-1995 	Phase 3 (C)	Estramustine & Vinblastine	Might have shorter OS
====Chemotherapy====
*Vinblastine (Velban) 4 mg/m2 IV bolus once per day on days 1, 8, 15, 22, 29, 36
8-week cycles
===References===
# Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Roth B; Hoosier Oncology Group; Fox Chase Network. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol. 1999 Oct;17(10):3160-6. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
Category:Prostate cancer regimens
Category:Historical regimens
Category:Disease-specific pages
Category:Male genital cancers